News | July 17, 2024
Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
The company will address these observations within the stipulated timeline
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
The company is planning to expand its plant capacity in in Vapi
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
The facility is a part of Lupin Manufacturing Solutions
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Subscribe To Our Newsletter & Stay Updated
